INDICATIONS

REBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.

REBLOZYL is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).

REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.

Request a Rep

Dosing and Administration: Dosing calculator

Choose a disease state:
Please enter your patient's weight (age 18+):
Type of dose:
Current dose
Current dose
Adverse reaction
Do not increase the dose if you believe the patient is experiencing an adverse reaction. Do not increase the dose more frequently than every 2 consecutive doses (6 weeks) or beyond the maximum dose of 1.75 mg/kg.
Insufficient response is defined as:
  • Not RBC transfusion-free after ≥2 consecutive doses at the 1 mg/kg and 1.33 mg/kg dose levels
  • No reduction in transfusion burden after ≥3 doses (9 weeks) at the 1.75 mg/kg dose level
For dose decrease for increase in Hgb only: Initiate a dose decrease if there is an increase in patient's Hgb by greater than 2 g/dL within 3 weeks in the absence of transfusions.

Please enter a weight between 74 lb and 337 lb.

Dosing for: MDS-associated anemia

Discontinue REBLOZYL after insufficient response, defined as no reduction in RBC transfusion burden after at least 3 consecutive doses (9 weeks) at maximum dose of 1.75 mg/kg.

DISCONTINUE REBLOZYL.

DISCONTINUE treatment.

INTERRUPT treatment and RESTART REBLOZYL at the next lower dose level when the adverse reaction resolves to no more than Grade 1*

Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe, and Grade 4 is life-threatening.

*If dose delay is >12 consecutive weeks, discontinue treatment. Follow dose decrease instructions for increase in Hgb or adverse reaction that resolved to Grade 1.

PATIENT WEIGHT
--
STARTING DOSE
(1 mg/kg)
--
RECONSTITUTED VOLUME
--

Assess and review Hgb results and transfusion record prior to each administration of REBLOZYL. If an RBC transfusion occurred prior to dosing, use the pretransfusion Hgb for dose evaluation. If predose Hgb is ≥11.5 g/dL in the absence of transfusions, interrupt treatment and restart when the Hgb is no more than 11 g/dL.


Divide doses requiring larger reconstituted volumes (ie, >1.2 mL) into separate, similar-volume injections and inject into separate sites. two syringe icons
Reblozyl SC injection site locations on the body include Upper Arms, Adbodmen, and Thighs

By using this resource, you agree to the following: This dosing calculator is being provided "AS IS" and is intended for use only by qualified healthcare providers. All calculations should be confirmed before use. Bristol Myers Squibb makes no claims as to the accuracy of the information contained herein. The information being provided is not a substitute for clinical judgment. Neither Bristol Myers Squibb, nor any other party involved in the preparation or publication of this site, shall be liable to you or others for any decisions made or actions taken by you or others in reliance on this information.

Dosing and Administration: Dosing calculator

Choose a disease state:
Please enter your patient's weight (age 18+):
Type of dose:
Current dose
Current dose
Adverse reaction
Do not increase the dose if you believe the patient is experiencing an adverse reaction. Do not increase the dose more frequently than every 2 consecutive doses (6 weeks) or beyond the maximum dose of 1.75 mg/kg.
Insufficient response is defined as:
  • Not RBC transfusion-free after ≥2 consecutive doses at the 1 mg/kg and 1.33 mg/kg dose levels
  • No reduction in transfusion burden after ≥3 doses (9 weeks) at the 1.75 mg/kg dose level
For dose decrease for increase in Hgb only: Initiate a dose decrease if there is an increase in patient's Hgb by greater than 2 g/dL within 3 weeks in the absence of transfusions.

Please enter a weight between 74 lb and 337 lb.

Dosing for: MDS-associated anemia

Discontinue REBLOZYL after insufficient response, defined as no reduction in RBC transfusion burden after at least 3 consecutive doses (9 weeks) at maximum dose of 1.75 mg/kg.

DISCONTINUE REBLOZYL.

DISCONTINUE treatment.

INTERRUPT treatment and RESTART REBLOZYL at the next lower dose level when the adverse reaction resolves to no more than Grade 1*

Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe, and Grade 4 is life-threatening.

*If dose delay is >12 consecutive weeks, discontinue treatment. Follow dose decrease instructions for increase in Hgb or adverse reaction that resolved to Grade 1.

PATIENT WEIGHT
--
STARTING DOSE
(1 mg/kg)
--
RECONSTITUTED VOLUME
--

Assess and review Hgb results and transfusion record prior to each administration of REBLOZYL. If an RBC transfusion occurred prior to dosing, use the pretransfusion Hgb for dose evaluation. If predose Hgb is ≥11.5 g/dL in the absence of transfusions, interrupt treatment and restart when the Hgb is no more than 11 g/dL.


Divide doses requiring larger reconstituted volumes (ie, >1.2 mL) into separate, similar-volume injections and inject into separate sites. two syringe icons
Reblozyl SC injection site locations on the body include Upper Arms, Adbodmen, and Thighs

By using this resource, you agree to the following: This dosing calculator is being provided "AS IS" and is intended for use only by qualified healthcare providers. All calculations should be confirmed before use. Bristol Myers Squibb makes no claims as to the accuracy of the information contained herein. The information being provided is not a substitute for clinical judgment. Neither Bristol Myers Squibb, nor any other party involved in the preparation or publication of this site, shall be liable to you or others for any decisions made or actions taken by you or others in reliance on this information.